Priority Assets


Our Priority Assets are largely maturing clinical development companies, nearing significant value inflection points.

Kymab is a clinical-stage therapeutic antibody company based in Cambridge, UK, with a novel approach to the generation of fully human monoclonal antibodies.

Kymab was the first spin-out from The Wellcome Trust Sanger Institute, and is deploying its best-in-class antibody platform to build a pipeline of differentiated drug candidates by utilising its proprietary KymouseTM platform, a mouse-model that can generate fully human monoclonal antibodies.

Kymab’s platform spans across immuno-oncology, haematology, auto-immune and infectious diseases.

Alongside its wholly-owned programmes, Kymab has partnered with world-leading scientific and medical collaborators, including Heptares Therapeutics, and the Bill and Melinda Gates Foundation.

Kymab Pipeline

Candidate

Indication

IND-enabling

Phase 1

Phase 2

Phase 3

KY1005 - Anti-OX40L

Immunology (immune-mediated diseases)

KY1044 - Anti-ICOS agonist

Immuno-oncology (T-cell activation)

KY1043 - PD-L1 Immunocytokine

Immuno-oncology (novel bispecific)

Candidate: KY1005 - Anti-OX40L

Indication: Immunology (immune-mediated diseases)

IND-enabling

Phase 1

Phase 2

Phase 3


Candidate: KY1044 - Anti-ICOS agonist

Indication: Immuno-oncology (T-cell activation)

IND-enabling

Phase 1

Phase 2

Phase 3


Candidate: KY1043 - PD-L1 Immunocytokine

Indication: Immuno-oncology (novel bispecific)

IND-enabling

Phase 1

Phase 2

Phase 3